去甲斑蝥素通过诱导自噬体聚集促使乳腺癌MDA-MB-231细胞凋亡

夏源; 姜庆玲; 王晓婷; 李敏敬; 郑秋生; 李德芳

doi:10.11665/j.issn.1000-5048.2023033004

去甲斑蝥素通过诱导自噬体聚集促使乳腺癌MDA-MB-231细胞凋亡

夏源^1,2,3,
姜庆玲^2,3,
王晓婷³,
李敏敬³,
郑秋生^1,2,3,
李德芳^1,2,3

1.
石河子大学药学院新疆植物药物资源与利用教育部重点实验室，石河子 832061
2.
滨州医学院中西医结合学院山东省高等学校-中药活性成分生物合成与靶点发现特色实验室，烟台 264003
3.
滨州医学院中西医结合学院烟台市肿瘤代谢中药药理重点实验室，烟台 264003

基金项目: 国家自然科学基金资助项目（No.81872162）

计量
- 文章访问数: 167
- HTML全文浏览量: 14
- PDF下载量: 238
出版历程
- 收稿日期: 2023-03-29
- 修回日期: 2023-09-25
- 刊出日期: 2023-12-24

Norcantharidin induces apoptosis through autophagosome accumulation in breast cancer MDA-MB-231 cells

1.
Key Laboratory of Xinjiang Phytomedicine Resource and Utilization (Ministry of Education), School of Pharmacy, Shihezi University, Shihezi 832061
2.
Featured Laboratory for Biosynthesis and Target Discovery of Active Components of Traditional Chinese Medicine, School of Integrated Traditional Chinese and Western Medicine, Binzhou Medical University, Yantai 264003
3.
Yantai Key Laboratory of Pharmacology of Traditional Chinese Medicine in Tumor Metabolism, School of Integrated Traditional Chinese and Western Medicine, Binzhou Medical University, Yantai 264003, China

Funds: This study was supported by the National Natural Science Foundation of China (No.81872162)

摘要

摘要: 探究去甲斑蝥素（norcantharidin，NCTD）对三阴性乳腺癌MDA-MB-231细胞增殖和凋亡的影响。采用Western blot实验检测 NCTD对MDA-MB-231细胞中凋亡相关蛋白Bax/Bcl-2、cleaved-PARP/PARP、cleaved-caspase-9、cleaved-caspase-3和MCL-1表达水平的影响；采用Western blot实验检测NCTD对MDA-MB-231细胞中自噬相关蛋白LC3-II/LC3-I，Parkin和PINK1表达水平的影响；采用流式细胞术检测NCTD对MDA-MB-231细胞线粒体膜电位及线粒体活性氧（reactive oxygen species，ROS）变化情况的影响；采用共聚焦显微镜检测NCTD对表达mCherry-EGFP-LC3的MDA-MB-231细胞自噬流的影响；采用流式细胞术检测NCTD联合使用氯喹（chloroquine，CQ）或3-甲基腺嘌呤（3-methyladenine，3-MA）后，对MDA-MB-231细胞凋亡情况的影响。实验结果显示，NCTD可显著上调Bax/Bcl-2、cleaved-PARP/PARP、cleaved-caspase-9、cleaved-caspase-3以及LC3-II/LC3-I蛋白的表达水平，促进Parkin的线粒体易位，阻断自噬流。此外，NCTD联合使用CQ加剧了细胞凋亡，而NCTD联合使用3-MA则减少了细胞凋亡。研究结果表明，NCTD可以诱导自噬体积累并导致MDA-MB-231细胞凋亡。
- 乳腺癌 /
- MDA-MB-231细胞 /
- 去甲斑蝥素 /
- 凋亡 /
- 自噬
Abstract: The aim of this study was to investigate the effect of norcantharidin (NCTD) on the proliferation and apoptosis of triple-negative breast cancer cell line MDA-MB-231.Western blot was used to detect the effect of NCTD on the expression levels of apoptosis-related proteins Bax/Bcl-2, cleaved-PARP/PARP/PARP, cleved-caspase-9, cleaved-caspase-3 and MCL-1 in MDA-MB-231 cells.Also, the expression levels of autophagy-related proteins LC3-II/LC3-I, Parkin and PINK1 in MDA-MB-231 cells were measured by Western blot.Flow cytometry was used to measure the effect of NCTD on the changes of mitochondrial membrane potential and mitochondrial reactive oxygen species (ROS).The effect of NCTD on autophagy flow in cells expressing mCherry-EGFP-LC3 was detected by a confocal microscope.Moreover, the effects of NCTD combined with chloroquine (CQ) or 3-methyladenine (3-MA) on the apoptosis of MDA-MB-231 cells were detected by flow cytometry.The results showed that NCTD significantly increased the expression levels of Bax/Bcl-2, cleaved-PARP/PARP, cleaved-caspase-9, cleasved-caspase-3 and LC3-II/LC3-I proteins, and promoted the mitochondrial translocation of Parkin, and blocked the autophagic flow in MDA-MB-231 cells. Moreover, NCTD combined with CQ accelerated apoptosis, while NCTD combined with 3-MA decreased apoptosis.These results suggest that NCTD can induce autophagy accumulation and lead to apoptosis of MDA-MB-231 cells.
- breast cancer /
- MDA-MB-231 cells /
- norcantharidin /
- apoptosis /
- autophagy

HTML全文

参考文献(35)

[1]	Xu SL. Inhibitory effect of microRNA-100 on malignant transformation of breast cells and its mechanism (MicroRNA-100对乳腺细胞恶性转化的抑制作用及其机制研究)[D]. Hefei: Anhui Medical University, 2019.
[2]	Song X, Yu ZY. Progression of anti-EGFR targeted therapy for triple negative breast cancer[J]. Chin J Cancer Prev Treat (中华肿瘤防治杂志), 2018, 25(3): 215-220.
[3]	Lou LP. Local recurrence risk and survival analysis of breast cancer patients with T1-2 and one to three positive axillary lymph nodes without postmastectomy radiotherapy (T1-2期伴1-3个腋窝淋巴结转移术后未行放射治疗的乳腺癌患者局部复发风险及生存分析)[D]. Tianjin: Tianjin Medical University，2019.
[4]	Chen XK, Tian HQ. Therapeutic status and progress of triple negative breast cancer[J]. West J Tradit Chin Med (西部中医药), 2018, 31(11): 135-140.
[5]	Wang JQ, Chen J, Sun XY, et al. A mechanism research of novel inhibitor of PAK1 inducing colorectal cancer DLD-1 apoptosis[J]. J China Pharm Univ (中国药科大学学报), 2018, 49(2): 229-237.
[6]	Yi HW，Liu GQ. Inhibition of hydrogen peroxide-induced PC12 cell apoptosis by modafinil[J]. J China Pharm Univ (中国药科大学学报)，2004，35(3) : 271-275.
[7]	Bhatti JS, Bhatti GK, Reddy PH. Mitochondrial dysfunction and oxidative stress in metabolic disorders - A step towards mitochondria based therapeutic strategies[J]. Biochim Biophys Acta Mol Basis Dis, 2017, 1863(5): 1066-1077.
[8]	Heslop KA, Rovini A, Hunt EG, et al. JNK activation and translocation to mitochondria mediates mitochondrial dysfunction and cell death induced by VDAC opening and sorafenib in hepatocarcinoma cells[J]. Biochem Pharmacol, 2020, 171: 113728.
[9]	Zhu WJ, Liu F, Wang L, et al. pPolyHb protects myocardial H9C2 cells against ischemia-reperfusion injury by regulating the Pink1-Parkin-mediated mitochondrial autophagy pathway[J]. Artif Cells Nanomed Biotechnol, 2019, 47(1): 1248-1255.
[10]	Chen Y, Chen HN, Wang K, et al. Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinoma[J]. J Hepatol, 2019, 70(1): 66-77.
[11]	Green DR, Levine B. To be or not to be? How selective autophagy and cell death govern cell fate[J]. Cell, 2014, 157(1): 65-75.
[12]	Lyamzaev KG, Tokarchuk AV, Panteleeva AA, et al. Induction of autophagy by depolarization of mitochondria[J]. Autophagy, 2018, 14(5): 921-924.
[13]	Mao JY. Chinese medicine on the treatment of tri-negative breast cancer: meta-analysis and clinical research (中医药治疗三阴性乳腺癌的Meta分析及临床研究) [D]. Nanjing: Nanjing University of Chinese Medicine, 2018.
[14]	Li XY, Guan QX, Shang YZ, et al. Metal-organic framework IRMOFs coated with a temperature-sensitive gel delivering norcantharidin to treat liver cancer[J]. World J Gastroenterol, 2021, 27(26): 4208-4220.
[15]	Deng LP, Dong J, Cai H, et al. Cantharidin as an antitumor agent: a retrospective review[J]. Curr Med Chem, 2013, 20(2): 159-166.
[16]	Zhang XM, Zhang BF, Zhang PH, et al. Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells[J]. PLoS One, 2019, 14(5): e0217181.
[17]	Liu WH, Chen CG, Gu XJ, et al. AM1241 alleviates myocardial ischemia-reperfusion injury in rats by enhancing Pink1/Parkin-mediated autophagy[J]. Life Sci, 2021, 272: 119228.
[18]	Barazzuol L, Giamogante F, Brini M, et al. PINK1/parkin mediated mitophagy, Ca²⁺ signalling, and ER-mitochondria contacts in Parkinson’s disease[J]. Int J Mol Sci, 2020, 21(5): 1772.
[19]	Jeong SJ, Zhang XY, Rodriguez-Velez A, et al. p62/SQSTM1 and selective autophagy in cardiometabolic diseases[J]. Antioxid Redox Signal, 2019, 31(6): 458-471.
[20]	Deng ZQ, Lim J, Wang Q, et al. ALS-FTLD-linked mutations of SQSTM1/p62 disrupt selective autophagy and NFE2L2/NRF₂ anti-oxidative stress pathway[J]. Autophagy, 2020, 16(5): 917-931.
[21]	Lin XL, Li S, Zhao Y, et al. Interaction domains of p62: a bridge between p62 and selective autophagy[J]. DNA Cell Biol, 2013, 32(5): 220-227.
[22]	Ye K, Wei QY, Gong ZF, et al. Effect of norcantharidin on the proliferation, apoptosis, and cell cycle of human mesangial cells[J]. Ren Fail, 2017, 39(1): 458-464.
[23]	Yan ZJ, Yang K, Tang X, et al. Norcantharidin nanostructured lipid carrier (NCTD-NLC) suppresses the viability of human hepatocellular carcinoma HepG2 cells and accelerates the apoptosis[J]. J Immunol Res, 2022, 2022: 3851604.
[24]	Ahn CH, Hong KO, Jin B, et al. Contribution of p38 MAPK pathway to norcantharidin-induced programmed cell death in human oral squamous cell carcinoma[J]. Int J Mol Sci, 2019, 20(14): 3487.
[25]	Wang JS, Xiao XS, Zhang Y, et al. Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells[J]. J Pineal Res, 2012, 53(1): 77-90.
[26]	Liu JL, Zhang LC. Correlation of mitochondrial dysfunction and inflammation with aging[J]. Chin J Mult Organ Dis Elder (中华老年多器官疾病杂志), 2019, 18(6): 469-472.
[27]	Liu X, Wu J, Wang J, et al. Mitochondrial dysfunction is involved in aristolochic acid I-induced apoptosis in renal proximal tubular epithelial cells[J]. Hum Exp Toxicol, 2020, 39(5): 673-682.
[28]	Li LZ, Zhao ZM, Zhang L, et al. Atorvastatin induces mitochondrial dysfunction and cell apoptosis in HepG2 cells via inhibition of the Nrf2 pathway[J]. J Appl Toxicol, 2019, 39(10): 1394-1404.
[29]	Hynes J, Nadanaciva S, Swiss R, et al. A high-throughput dual parameter assay for assessing drug-induced mitochondrial dysfunction provides additional predictivity over two established mitochondrial toxicity assays[J]. Toxicol In Vitro, 2013, 27(2): 560-569.
[30]	Sun Y, Jiang YM, Huang JT, et al. CISD2 enhances the chemosensitivity of gastric cancer through the enhancement of 5-FU-induced apoptosis and the inhibition of autophagy by AKT/mTOR pathway[J]. Cancer Med, 2017, 6(10): 2331-2346.
[31]	Hu P, Gou XQ, Cheng Y, et al. Effects of DENV-2 infection on autophagosome formation, autophage-lysosome fusion, and lysosomal degradation pathway in HUVECs[J]. J Guizhou Med Univ (贵州医科大学学报), 2022, 47(11): 1274-1280, 1287.
[32]	Tang Y, Wu H, Shao BZ, et al. Celosins inhibit atherosclerosis in ApoE^-/- mice and promote autophagy flow[J]. J Ethnopharmacol, 2018, 215: 74-82.
[33]	Tanaka S, Hikita H, Tatsumi T, et al. Rubicon inhibits autophagy and accelerates hepatocyte apoptosis and lipid accumulation in nonalcoholic fatty liver disease in mice[J]. Hepatology, 2016, 64(6): 1994-2014.
[34]	Vera-Ramirez L, Vodnala SK, Nini R, et al. Autophagy promotes the survival of dormant breast cancer cells and metastatic tumour recurrence[J]. Nat Commun, 2018, 9(1): 1944.
[35]	Dolma S, Selvadurai HJ, Lan XY, et al. Inhibition of dopamine receptor D4 impedes autophagic flux, proliferation, and survival of glioblastoma stem cells[J]. Cancer Cell, 2016, 29(6): 859-873.